Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab

Journal of Thrombosis and Haemostasis

Volumn 16, Issue 6, 2018, Pages 1078-1088

  Nogami, K ^a   Matsumoto, T ^a   Tabuchi, Y ^b   Soeda, T ^c   Arai, N ^b   Kitazawa, T ^c   Shima, M ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b SYSMEX CORPORATION   (Japan)

^c CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

bypassing agents; clot waveform analysis; emicizumab; FVIII; PT APTT

Indexed keywords

EMICIZUMAB; BISPECIFIC ANTIBODY; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 9A; COAGULATING AGENT; MONOCLONAL ANTIBODY;

ACTIVATED PARTIAL PROTHROMBIN TIME; ANIMAL CELL; ARTICLE; BLOOD ANALYSIS; BLOOD CLOTTING; BLOOD CLOTTING TIME; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLOT WAVEFORM ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; EX VIVO STUDY; FEMALE; HEMOPHILIA A; HEMOSTASIS; HUMAN; MAXIMUM REACTION VELOCITY; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; PROTHROMBIN TIME; BLOOD; CASE CONTROL STUDY; DRUG EFFECT; PARTIAL THROMBOPLASTIN TIME; PREDICTIVE VALUE; REPRODUCIBILITY;

ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD COAGULATION; CASE-CONTROL STUDIES; COAGULANTS; FACTOR IXA; FACTOR X; HEMOPHILIA A; HUMANS; PARTIAL THROMBOPLASTIN TIME; PREDICTIVE VALUE OF TESTS; PROTHROMBIN TIME; REPRODUCIBILITY OF RESULTS;

EID: 85047426922     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.14022     Document Type: Article

References (27)

1. Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, Ludlam CA, Mahlangu JN, Mulder K, Poon MC, Street A; Treatment Guidelines Working Group on Behalf of the World Federation of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1–47.
2. Beeton K, Neal D, Watson T, Lee CA. Parents of children with haemophilia – a transforming experience. Haemophilia 2007; 13: 570–9.
3. De Moerloose P, Urbancik W, Van Den Berg HM, Richards M. A survey of adherence to haemophilia therapy in six European countries: results and recommendations. Haemophilia 2008; 14: 931–8.
4. Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol 2013; 4: 59–72.
5. Caram C, de Souza RG, de Sousa JC, Araújo Pereira T, do Amaral Cerqueira AM, van der Bom JG, Rezende SM. The long-term course of factor VIII inhibitors in patients with congenital haemophilia A without immune tolerance induction. Thromb Haemost 2011; 105: 59–65.
6. Kitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, Soeda T, Yoshihashi K, Okuyama-Nishida Y, Saito H, Tsunoda H, Suzuki T, Adachi H, Miyazaki T, Ishii S, Kamata-Sakurai M, Iida T, Harada A, Esaki K, Funaki M, Moriyama C, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 2012; 18: 1570–4.
7. Kitazawa T, Esaki K, Tachibana T, Ishii S, Soeda T, Muto A, Kawabe Y, Tomoyuki I, Tsunoda H, Nogami K, Shima M, Hattori H. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost 2017; 117: 1348–57.
8. Shima M, Hanabusa H, Taki M, Matsushita T, Sato T, Fukutake K, Fukazawa N, Yoneyama K, Yoshida H, Nogami K. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med 2016; 374: 2044–53.
9. Shima M, Hanabusa H, Taki M, Matsushita T, Sato T, Fukutake K, Kasai R, Yoneyama K, Yoshida H, Nogami K. Long-term safety and efficacy of emicizumab in a phase 1/2 study in hemophilia A patients with or without inhibitors. Blood Advances 2017; 1: 1891–9.
10. Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Valente N, Asikanius E, Levy GG, Windyga J, Shima M. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med 2017; 377: 809–18.
11. Uchida N, Sambe T, Yoneyama K, Fukazawa N, Kawanishi T, Kobayashi S, Shima M. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood 2016; 127: 1633–41.
12. Braun PJ, Givens TB, Stead AG, Beck LR, Gooch SA, Swan RJ, Fischer TJ. Properties of optical data from activated partial thromboplastin time and prothrombin time assays. Thromb Haemost 1997; 78: 1079–87.
13. Shima M, Thachil J, Nair SC, Srivastava A. Towards standardization of clot waveform analysis and recommendations for its clinical applications. J Thromb Haemost 2013; 11: 1417–20.
14. Shima M, Matsumoto T, Ogiwara K. New assays for monitoring haemophilia treatment. Haemophilia 2008; 14(Suppl. 3): 83–92.
15. Shima M, Matsumoto T, Fukuda K, Kubota Y, Tanaka I, Nishiya K, Giles AR, Yoshioka A. The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C). Thromb Haemost 2002; 87: 436–41.
16. Matsumoto T, Shima M, Takeyama M, Yoshida K, Tanaka I, Sakurai Y, Giles AR, Yoshioka A. The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay. J Thromb Haemost 2006; 4: 377–84.
17. Matsumoto T, Nogami K, Tabuchi Y, Yada K, Ogiwara K, Kurono H, Arai N, Shima M. Clot waveform analysis using CS-2000i™ distinguishes between very low and absent levels of factor VIII activity in patients with severe hemophilia A. Haemophilia 2017; 23: e427–35.
18. Haku J, Nogami K, Matsumoto T, Ogiwara K, Shima M. Optimal monitoring of bypass-therapy in hemophilia A patients with inhibitor using clot waveform analysis. J Thromb Haemost 2014; 12: 355–62.
19. Sampei Z, Igawa T, Soeda T, Okuyama-Nishida Y, Moriyama C, Wakabayashi T, Tanaka E, Muto A, Kojima T, Kitazawa T, Yoshihashi K, Harada A, Funaki M, Haraya K, Tachibana T, Suzuki S, Esaki K, Nabuchi Y, Hattori K. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS ONE 2013; 8: e57479.
20. Muto A, Yoshihashi K, Takeda M, Kitazawa T, Soeda T, Igawa T, Sakamoto Y, Haraya K, Kawabe Y, Shima M, Yoshioka A, Hattori K. Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. J Thromb Haemost 2014; 12: 206–13.
21. Hoffman M. Remodeling the blood coagulation cascade. J Thromb Thrombolysis 2003; 16: 17–20.
22. Monroe DM. Further understanding of recombinant activated factor VII mode of action. Semin Hematol 2008; 45(2 Suppl. 1): S7–11.
23. ® in prophylactic therapy. Haemophilia 2016; 22: 615–24.
24. Trossaërt M, Boisseau P, Quemener A, Sigaud M, Fouassier M, Ternisien C, Lefrançois-Bettembourg A, Tesson C, Thomas C, Bezieau S. Prevalence, biological phenotype and genotype in moderate/mild hemophilia A with discrepancy between one-stage and chromogenic factor VIII activity. J Thromb Haemost 2011; 9: 524–30.
25. Nogami K, Shima M. Phenotypic heterogeneity of hemostasis in severe hemophilia. Semin Thromb Hemost 2015; 41: 826–31.
26. Yada K, Nogami K, Wakabayashi H, Fay PJ, Shima M. The mild phenotype in severe hemophilia A with Arg1781His mutation is associated with enhanced binding affinity of factor VIII for factor X. Thromb Haemost 2013; 109: 1007–15.
27. Minami H, Nogami K, Kitazawa T, Hattori K, Shima M. FVIIIa mimicking bispecific antibody, ACE910 improves in vitro coagulation function of FXI deficiency patient's plasma. J Thromb Haemost 2015; 13(Suppl. 2): 439.